StockNews.com initiated coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research note issued to investors on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Shares of OTIC stock opened at $0.01 on Friday. Otonomy has a 1 year low of $0.01 and a 1 year high of $2.54. The firm has a fifty day moving average price of $0.10 and a 200-day moving average price of $0.11. The company has a market cap of $582,479.50, a price-to-earnings ratio of -0.01 and a beta of 1.54.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L. P. bought a new position in shares of  Otonomy during the third quarter valued at approximately $1,621,000.  Lynx1 Capital Management LP boosted its stake in shares of  Otonomy by 7,609.6% during the third quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company’s stock valued at $682,000 after purchasing an additional 2,282,880 shares in the last quarter.  Requisite Capital Management LLC bought a new position in shares of  Otonomy during the third quarter valued at approximately $44,000.  Dimensional Fund Advisors LP boosted its stake in  Otonomy by 17.7% in the first quarter. Dimensional Fund Advisors LP now owns 841,694 shares of the biopharmaceutical company’s stock valued at $2,020,000 after acquiring an additional 126,747 shares in the last quarter.  Finally, Two Sigma Investments LP boosted its stake in  Otonomy by 129.2% in the third quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 80,153 shares in the last quarter. 41.23% of the stock is owned by hedge funds and other institutional investors.

Otonomy, Inc operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere’s disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss.

Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.